# Official Website: Thera-T Pharmaceutics

**Type:** source
**Status:** Useful
**Confidence:** Medium
**Source Type:** Official Website
**URL:** https://thera-tpharmaceutics.com
**Publisher:** Thera-T Pharmaceutics
**Accessed:** 2026-06-19
**Updated:** 2026-06-19

## Summary

Thera-T Pharmaceutics maintains a public website at thera-tpharmaceutics.com describing its MATCH (Multi-Antigen T-Cell Hybridizers) platform for blood cancer immunotherapy. Supporting sources include a TechBuzz News profile and a peer-reviewed publication in *Advanced Healthcare Materials* (2025) describing self-assembling multi-antigen T-cell hybridizers for multiple myeloma. The University of Utah's 2025 Breakthrough Technology of the Year award provides additional institutional corroboration. Together these sources provide medium-confidence grounding for the venture page's core claims about the mechanism, founder, incubation context, and funding level.

## Useful Claims

- MATCH (Multi-Antigen T-Cell Hybridizers) are self-assembling two-component constructs that direct T cells to multiple cancer antigens simultaneously.
- Targets: B-cell leukemia, non-Hodgkin lymphoma, and multiple myeloma.
- The design requires no viral manufacturing, distinguishing it from current CAR-T approaches.
- Founder: Tommy Gambles (postdoctoral researcher, U of U College of Pharmacy).
- Scientific basis: Dr. Jindřich Kopeček's polymer immunotherapy laboratory at U of U.
- Incubated at U2TAH (Huntsman Cancer Institute therapeutics accelerator).
- Approximately $400K in funding raised; animal studies ongoing as of the legacy intake date.
- University of Utah 2025 Breakthrough Technology of the Year.
- Peer-reviewed publication: "Self-Assembling Multi-Antigen T Cell Hybridizers for Multiple Myeloma," *Advanced Healthcare Materials* (2025).

## Reliability Notes

The official website is self-reported. The *Advanced Healthcare Materials* publication and TechBuzz profile provide independent corroboration of the mechanism and company existence. The University of Utah award is an institutional third-party validation. Funding figures ($400K) and animal study status reflect the intake period and should be verified from current sources. The AI-guided dosing model is described in company materials but has limited independent corroboration at this stage.

## Related Pages

- [Thera-T Pharmaceutics](thera-t-pharmaceutics.md)